DMIIR
Drugs Made In America Acquisition II Corp. RightNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
—
52W High
$0.17
52W Low
$0.06
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Drugs Made In America Acquisition II Corp. Right
Drugs Made In America Acquisition II Corp. Right (DMIIR) is a special purpose acquisition company focused on identifying and merging with innovative companies in the pharmaceutical sector to enhance domestic drug manufacturing. With a seasoned management team possessing extensive industry experience, DMIIR aims to capitalize on the increasing demand for accessible, affordable, and sustainable U.S.-produced medicines. By pursuing transformative opportunities within this sector, DMIIR not only seeks to generate significant shareholder value but also contributes to the development of vital infrastructure in the American healthcare landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | -812,113 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -0.32% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.26 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $50.26M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
53.94%
HV 20-Day
74.47%
HV 30-Day
125.40%
HV 60-Day
110.78%
HV Rank
—
Volatility is currently contracting
Data last updated: 5/5/2026